
CAR-T vs TIL vs NK: A Scientist’s Practical Guide to Immune Cell Therapy Selection (2026)
As a pharmacology professor with 20 years of research experience, I aim to clarify the confusion surrounding three major immune cell therapies—CAR-T, TIL, and NK. Based on 8 clinical studies in 2026, this blog uses plain language and real clinical data to compare their mechanisms, applicable populations, treatment effects, and key differences. It also addresses common pitfalls and provides a practical selection matrix, helping cancer patients avoid wrong choices and emphasizing that "safety is the first premise of comprehensive treatment."



